共 328 条
[1]
Bushby K(2010)Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management Lancet Neurol 9 77-93
[2]
Finkel R(2015)Contemporary cardiac issues in Duchenne muscular dystrophy. Working Group of the National Heart, Lung, and Blood Institute in collaboration with Parent Project Muscular Dystrophy Circulation 131 1590-1598
[3]
Birnkrant DJ(2009)Circumferential strain analysis identifies strata of cardiomyopathy in Duchenne muscular dystrophy: a cardiac magnetic resonance tagging study J Am Coll Cardiol 53 1204-1210
[4]
Case LE(2014)Left ventricular systolic function and the pattern of late-gadolinium-enhancement independently and additively predict adverse cardiac events in muscular dystrophy patients J Cardiovasc Magn Reson 16 81-179
[5]
Clemens PR(2014)Treatment of dystrophin cardiomyopathies Nat Rev Cardiol 11 168-51
[6]
Cripe L(2011)Duchenne muscular dystrophy: survival by cardio-respiratory interventions Neuromuscul Disord 21 47-8855
[7]
McNally EM(2015)Current understanding of molecular pathology and treatment of cardiomyopathy in duchenne muscular dystrophy Molecules 20 8823-773
[8]
Kaltman JR(2007)Dystrophic cardiomyopathy: amplification of cellular damage by Ca2+ signalling and reactive oxygen species-generating pathways Cardiovasc Res 77 766-129
[9]
Benson DW(2007)Metabolic and signaling alterations in dystrophin-deficient hearts precede overt cardiomyopathy J Mol Cell Cardiol 43 119-54
[10]
Canter CE(2019)Phase 1 Study of Edasalonexent (CAT-1004), an Oral NF-kappaB Inhibitor, in Pediatric Patients with Duchenne Muscular Dystrophy J Neuromuscul Dis 6 43-91